文献速递心律失常

80岁及以上房颤患者依度沙班减量:ENGAGE AF-TIMI 48 事后分析

Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该研究为 ENGAGE AF-TIMI 48 随机临床试验的事后分析,聚焦 80 岁及以上房颤患者。在无减量指征的 1138 例患者中,依度沙班 60 mg 较 30 mg 大出血更多而疗效终点无差异;在 2406 例患者中,依度沙班 30 mg 较华法林净临床结局、大出血和死亡更低,卒中或体循环栓塞无差异。

要点

  • 80岁及以上无减量指征者,依度沙班60 mg较30 mg大出血增加而疗效无差异。
  • 80岁及以上患者依度沙班30 mg较华法林净临床结局、大出血和死亡更低。
  • 即使无减量指征,80岁及以上房颤患者可考虑依度沙班30 mg。

核心结论

  • 在80岁及以上房颤患者中,依度沙班30 mg每日一次较60 mg(无减量指征者)或华法林(不论减量状态)大出血更低,且缺血事件未增加。

研究设计与样本

  • ENGAGE AF-TIMI 48 为平行设计、双盲、全球临床试验,将房颤患者随机分配至两种依度沙班方案或华法林。
  • 本分析纳入2966例80岁及以上患者(平均年龄83岁,SD 2.7;男性1671例,56%)。
  • 分析包括无减量指征者依度沙班60 mg vs 30 mg,以及有或无减量指征者依度沙班30 mg vs 华法林。

主要发现

  • 依度沙班30 mg vs 华法林卒中或体循环栓塞发生率相当。

临床怎么用

  • 对于80岁及以上房颤患者,即使无减量指征,可考虑使用依度沙班30 mg每日一次以降低大出血风险。

局限性

  • 本分析为ENGAGE AF-TIMI 48的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data. OBJECTIVE: To evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60 mg vs 30 mg, and edoxaban, 30 mg vs warfarin. DESIGN, SETTING, AND PARTICIPANTS: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a parallel-design, double-blind, global clinical trial that randomized patients with atrial fibrillation to either one of 2 edoxaban dosing regimens or warfarin. This secondary analysis focused on patients 80 years or older without dose-reduction criteria receiving edoxaban, 60 mg vs 30 mg, as well as patients with or without dose-reduction criteria receiving edoxaban, 30 mg, vs warfarin. Study data were analyzed between October 2022 and December 2023. INTERVENTIONS: Oral edoxaban, 30 mg once daily; edoxaban, 60 mg once daily; or warfarin. MAIN OUTCOMES AND MEASURES: Primary net clinical outcome of death, stroke or systemic embolism, and major bleeding and each individual component. RESULTS: The current analysis included 2966 patients 80 years and older (mean [SD] age, 83 [2.7] years; 1671 male [56%]). Among 1138 patients 80 years and older without dose-reduction criteria, those receiving edoxaban, 60 mg vs 30 mg, had more major bleeding events (hazard ratio [HR], 1.57; 95% CI, 1.04-2.38; P = .03), particularly gastrointestinal hemorrhage (HR, 2.24; 95% CI, 1.29-3.90; P = .004), with no significant difference in efficacy end points. Findings were supported by analyses of endogenous factor Xa inhibition, a marker of anticoagulant effect, which was comparable between younger patients receiving edoxaban, 60 mg, and older patients receiving edoxaban, 30 mg. In 2406 patients 80 years and older with or without dose-reduction criteria, patients receiving edoxaban, 30 mg, vs warfarin had lower rates of the primary net clinical outcome (HR, 0.78; 95% CI, 0.68-0.91; P = .001), major bleeding (HR, 0.59; 95% CI, 0.45-0.77; P < .001), and death (HR, 0.83; 95% CI, 0.70-1.00; P = .046), whereas rates of stroke or systemic embolism were comparable. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial, in patients 80 years and older with atrial fibrillation, major bleeding events were lower in patients randomized to receive edoxaban, 30 mg per day, compared with either edoxaban, 60 mg per day (in patients without dose-reduction criteria), or warfarin (irrespective of dose-reduction status), without an offsetting increase in ischemic events. These data support the concept that lower-dose anticoagulants, such as edoxaban, 30 mg, may be considered in older patients with atrial fibrillation even in the absence of dose-reduction criteria. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00781391.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Zimerman, Braunwald, Steffel, et al. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38985461. doi:10.1001/jamacardio.2024.1793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。